BerandaMVIR • STO
add
Medivir AB
Tutup sebelumnya
kr 1,63
Rentang hari
kr 1,63 - kr 1,70
Rentang tahun
kr 1,06 - kr 3,99
Kapitalisasi pasar
190,25Â jt SEK
Volume Rata-Rata
363,98Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
STO
Berita pasar
FXStreet
8 jam yang lalu
Dow Jones Meloncat Naik setelah Pengumuman Kesepakatan Perdagangan AS-Inggris
0,62%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (SEK) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 600,00Â rb | 20,00% |
Biaya operasional | 8,10Â jt | 10,96% |
Laba bersih | -13,30Â jt | 49,04% |
Margin laba bersih | -2,22Â rb | 57,54% |
Penghasilan per saham | -0,12 | 47,83% |
EBITDA | -13,57Â jt | 49,37% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (SEK) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 35,10Â jt | -77,13% |
Total aset | 144,00Â jt | -45,95% |
Total liabilitas | 41,40Â jt | -24,59% |
Total ekuitas | 102,60 jt | — |
Saham yang beredar | 112,17 jt | — |
Harga terhadap nilai buku | 1,80 | — |
Tingkat pengembalian aset | -21,48% | — |
Tingkat pengembalian modal | -28,67% | — |
Arus Kas
Perubahan kas bersih
| (SEK) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -13,30Â jt | 49,04% |
Kas dari operasi | -26,80Â jt | 23,43% |
Kas dari investasi | — | — |
Kas dari pembiayaan | -700,00Â rb | -103,70% |
Perubahan kas bersih | -27,40Â jt | -70,19% |
Arus kas bebas | -21,39Â jt | 15,85% |
Tentang
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Didirikan
1988
Situs
Karyawan
10
